1
Pieter R Cullis, Michael J Hope, Marcel B Bally: Extrusion technique for producing unilamellar vesicles. The Liposome Company, Allen Bloom, Catherine Kurtz, Ronald G Ort, April 16, 1991: US05008050 (160 worldwide citation)

A method for reducing the lamellarity of a population of liposomes is provided which comprises repeatedly passing the liposomes under pressure through a filter which has a pore size equal to or less than about 100 nm. In certain embodiments, the method is used to convert a population of previously f ...


2
Mircea Popescu, Christine E Swenson, Sterling C Johnson, Robert P Lenk: Therapeutic treatment by intramammary infusion. The Liposome Company, Allen Bloom, Thomas M Saunders, Ronald G Ort, January 1, 1991: US04981692 (78 worldwide citation)

A method of treating, by intramammary infusion of liposomes, Brucella spp. infections in an animal by administration of a therapeutically effective amount of aminoglycoside in liposome form, also being a method of administering a therapeutic agent in liposome form to a proximal mammary lymph node or ...


3
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Mircea C Popescu, Steven J Weiss, Richard S Ginsberg, Marc J Ostro, Sol M Gruner: Stable plurilamellar vesicles. The Liposome Company, Allen Bloom, Ronald G Ort, December 8, 1992: US05169637 (71 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing ...


4
Lois E Bolcsak, Lawrence Boni, Mircea C Popescu, Paul A Tremblay: Steroidal liposomes exhibiting enhanced stability. The Liposome Company, Allen Bloom, Ronald G Ort, March 31, 1992: US05100662 (68 worldwide citation)

The present invention relates to novel liposomes and liposome-like structures (vesicles) comprising an amount of a derivatized sterol either alone or in combination with additional liposome-forming lipids.


5
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Mircea C Popescu, Steven J Weiss, Richard S Ginsberg, Marc J Ostro, Sol M Gruner: Stable plurilamellar vesicles. The Liposome Company, Allen Bloom, Thomas M Saunders, Ronald G Ort, July 9, 1991: US05030453 (68 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing ...


6
Chiin H Hsiao: Dry sustained release theophylline oral formulation. Key Pharmaceuticals, Sybil Meloy, Ronald G Ort, May 6, 1986: US04587118 (63 worldwide citation)

A dry sustained release oral dosage formulation of theophylline and a method of orally administering theophylline is disclosed. The oral formulation is comprised of a capsule which includes upper and lower parts which are connectible and easily separable from each other, and a plurality of micropell ...


7
Marc Nazare, Volkmar Wehner, David William Will, Hans Matter: Pyrazole-derivatives as factor Xa inhibitors. Sanofi Aventis Deutschland, Ronald G Ort, Scully Scott Murphy and Presser P C, March 22, 2011: US07910606 (61 worldwide citation)

The present invention is directed to a compound of formula I, in which R0; R1; R2; R3; R4; Q; V, G and M have the meanings indicated below. The compound of formula I is a pharmacologically active compound. It exhibits a strong anti-thrombotic effect and is suitable, for example, for the therapy and ...


8
Karl Theodor Kraemer, Karl Heinz Nietsch, Rainer Pooth, Uwe Muenster, Wolfgang Mehnert, Monika Schaefer Korting: Preparations for topical administration of substances having antiandrogenic activity. Aventis Pharma Deutschland, Ronald G Ort, April 5, 2005: US06875438 (44 worldwide citation)

A preparation comprising at least one form of lipid nanoparticles or a nanoemulsion comprising at least one compound of the formula I and/or one stereoisomeric form of the compound of the formula I and/or one physiologically tolerated salt of the compound of the formula I, in which R1 is —(C5-C17)-a ...


9
Michael W Fountain, Steven J Weiss, Robert P Lenk, Mircea C Popescu, Richard S Ginsberg: Enhancement of pharmaceutical activity. The Liposome Company, Allen Bloom, Thomas S Saunders, Ronald G Ort, March 19, 1991: US05000958 (38 worldwide citation)

The invention encompasses mixtures of antimicrobial agents coencapsulated in liposomes which when administered in vivo exert an enhanced therapeutic effect. The therapeutic effectiveness of the coencapsulated antimocrobial agents is greater than that of the same combination administered either in so ...


10
Hugues D Orchymont, Luc Van Hijfte, Andre Zimmermann: Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors. sanofi aventis, Ronald G Ort, January 27, 2009: US07482342 (35 worldwide citation)

Compound corresponding to general formula (I): in which, R1 represents a hydrogen or halogen atom, an NH2, NHR2, NHCOR2, NO2, CN, CH2NH2 and CH2NHR2; or alternatively R1 represents an optionally substituted phenyl or an optionally substituted heteroaromatic group; Ar represents an optionally substit ...